Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Neoplasms 2Melanoma 2Solid Tumors 1Recurrence 1Lymphoma, B-Cell 1Advanced/Metastatic Solid Tumors 1Adenocarcinoma Pancreas 1

Interventions

pembrolizumab 92Nivolumab 56Ipilimumab 55Cyclophosphamide 52Vemurafenib 28fludarabine 27aldesleukin 25Interleukin-2 25fludarabine phosphate 21trametinib 20dabrafenib 17Temozolomide 14Biopsy 14Cisplatin 13spartalizumab 12atezolizumab 12Carboplatin 11cobimetinib 10Paclitaxel 10Introns 10CTLA-4 Antigen 10poly ICLC 9binimetinib 9Specimen Handling 9Radiotherapy 9Radiosurgery 9MART-1 Antigen 9tremelimumab 8incomplete Freund's adjuvant 8Radiation 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Melanoma × selicrelumab × Clear all
NCT01103635 2020-04-07

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Abramson Cancer Center at Penn Medicine

Phase 1 Completed
25 enrolled
Dermatologic

Melanoma

NCT01008527 2015-09-24

Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100

H. Lee Moffitt Cancer Center and Research Institute

Phase 1 Completed
22 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡